Cargando…
Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin
The persistence of drug resistant cell populations following chemotherapeutic treatment is a significant challenge in the clinical management of cancer. Resistant subpopulations arise via both cell intrinsic and extrinsic mechanisms. Extrinsic factors in the microenvironment, including neighboring c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134055/ https://www.ncbi.nlm.nih.gov/pubmed/30234012 http://dx.doi.org/10.3389/fonc.2018.00337 |
_version_ | 1783354602871062528 |
---|---|
author | Joyce, M. Hunter Lu, Carolyne James, Emily R. Hegab, Rachel Allen, Shane C. Suggs, Laura J. Brock, Amy |
author_facet | Joyce, M. Hunter Lu, Carolyne James, Emily R. Hegab, Rachel Allen, Shane C. Suggs, Laura J. Brock, Amy |
author_sort | Joyce, M. Hunter |
collection | PubMed |
description | The persistence of drug resistant cell populations following chemotherapeutic treatment is a significant challenge in the clinical management of cancer. Resistant subpopulations arise via both cell intrinsic and extrinsic mechanisms. Extrinsic factors in the microenvironment, including neighboring cells, glycosaminoglycans, and fibrous proteins impact therapy response. Elevated levels of extracellular fibrous proteins are associated with tumor progression and cause the surrounding tissue to stiffen through changes in structure and composition of the extracellular matrix (ECM). We sought to determine how this progressively stiffening microenvironment affects the sensitivity of breast cancer cells to chemotherapeutic treatment. MDA-MB-231 triple negative breast carcinoma cells cultured in a 3D alginate-based hydrogel system displayed a stiffness-dependent response to the chemotherapeutic doxorubicin. MCF7 breast carcinoma cells cultured in the same conditions did not exhibit this stiffness-dependent resistance to the drug. This differential therapeutic response was coordinated with nuclear translocation of YAP, a marker of mesenchymal differentiation. The stiffness-dependent response was lost when cells were transferred from 3D to monolayer cultures, suggesting that endpoint ECM conditions largely govern the response to doxorubicin. To further examine this response, we utilized a platform capable of dynamic ECM stiffness modulation to allow for a change in matrix stiffness over time. We found that MDA-MB-231 cells have a stiffness-dependent resistance to doxorubicin and that duration of exposure to ECM stiffness is sufficient to modulate this response. These results indicate the need for additional tools to integrate mechanical stiffness with therapeutic response and inform decisions for more effective use of chemotherapeutics in the clinic. |
format | Online Article Text |
id | pubmed-6134055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61340552018-09-19 Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin Joyce, M. Hunter Lu, Carolyne James, Emily R. Hegab, Rachel Allen, Shane C. Suggs, Laura J. Brock, Amy Front Oncol Oncology The persistence of drug resistant cell populations following chemotherapeutic treatment is a significant challenge in the clinical management of cancer. Resistant subpopulations arise via both cell intrinsic and extrinsic mechanisms. Extrinsic factors in the microenvironment, including neighboring cells, glycosaminoglycans, and fibrous proteins impact therapy response. Elevated levels of extracellular fibrous proteins are associated with tumor progression and cause the surrounding tissue to stiffen through changes in structure and composition of the extracellular matrix (ECM). We sought to determine how this progressively stiffening microenvironment affects the sensitivity of breast cancer cells to chemotherapeutic treatment. MDA-MB-231 triple negative breast carcinoma cells cultured in a 3D alginate-based hydrogel system displayed a stiffness-dependent response to the chemotherapeutic doxorubicin. MCF7 breast carcinoma cells cultured in the same conditions did not exhibit this stiffness-dependent resistance to the drug. This differential therapeutic response was coordinated with nuclear translocation of YAP, a marker of mesenchymal differentiation. The stiffness-dependent response was lost when cells were transferred from 3D to monolayer cultures, suggesting that endpoint ECM conditions largely govern the response to doxorubicin. To further examine this response, we utilized a platform capable of dynamic ECM stiffness modulation to allow for a change in matrix stiffness over time. We found that MDA-MB-231 cells have a stiffness-dependent resistance to doxorubicin and that duration of exposure to ECM stiffness is sufficient to modulate this response. These results indicate the need for additional tools to integrate mechanical stiffness with therapeutic response and inform decisions for more effective use of chemotherapeutics in the clinic. Frontiers Media S.A. 2018-09-05 /pmc/articles/PMC6134055/ /pubmed/30234012 http://dx.doi.org/10.3389/fonc.2018.00337 Text en Copyright © 2018 Joyce, Lu, James, Hegab, Allen, Suggs and Brock. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Joyce, M. Hunter Lu, Carolyne James, Emily R. Hegab, Rachel Allen, Shane C. Suggs, Laura J. Brock, Amy Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin |
title | Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin |
title_full | Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin |
title_fullStr | Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin |
title_full_unstemmed | Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin |
title_short | Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin |
title_sort | phenotypic basis for matrix stiffness-dependent chemoresistance of breast cancer cells to doxorubicin |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134055/ https://www.ncbi.nlm.nih.gov/pubmed/30234012 http://dx.doi.org/10.3389/fonc.2018.00337 |
work_keys_str_mv | AT joycemhunter phenotypicbasisformatrixstiffnessdependentchemoresistanceofbreastcancercellstodoxorubicin AT lucarolyne phenotypicbasisformatrixstiffnessdependentchemoresistanceofbreastcancercellstodoxorubicin AT jamesemilyr phenotypicbasisformatrixstiffnessdependentchemoresistanceofbreastcancercellstodoxorubicin AT hegabrachel phenotypicbasisformatrixstiffnessdependentchemoresistanceofbreastcancercellstodoxorubicin AT allenshanec phenotypicbasisformatrixstiffnessdependentchemoresistanceofbreastcancercellstodoxorubicin AT suggslauraj phenotypicbasisformatrixstiffnessdependentchemoresistanceofbreastcancercellstodoxorubicin AT brockamy phenotypicbasisformatrixstiffnessdependentchemoresistanceofbreastcancercellstodoxorubicin |